The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial.

MLA

Burger, Maximilian, et al. “The Application of Adjuvant Autologous Antravesical Macrophage Cell Therapy vs. BCG in Non-Muscle Invasive Bladder Cancer: A Multicenter, Randomized Trial.” Journal of Translational Medicine, vol. 8, June 2010, p. 54. EBSCOhost, https://doi.org/10.1186/1479-5876-8-54.

APA

Burger, M., Thiounn, N., Denzinger, S., Kondas, J., Benoit, G., Chapado, M. S., Jimenz-Cruz, F. J., Kisbenedek, L., Szabo, Z., Zsolt, D., Grimm, M. O., Romics, I., Thüroff, J. W., Kiss, T., Tombal, B., Wirth, M., Munsell, M., Mills, B., Koh, T., & Sherman, J. (2010). The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial. Journal of Translational Medicine, 8, 54. https://doi.org/10.1186/1479-5876-8-54

Chicago

Burger, Maximilian, Nicolas Thiounn, Stefan Denzinger, Jozsef Kondas, Gerard Benoit, Manuel S Chapado, Fernando J Jimenz-Cruz, et al. 2010. “The Application of Adjuvant Autologous Antravesical Macrophage Cell Therapy vs. BCG in Non-Muscle Invasive Bladder Cancer: A Multicenter, Randomized Trial.” Journal of Translational Medicine 8 (June): 54. doi:10.1186/1479-5876-8-54.